COVID-19: India’s new drug Nirmacom gets approval from WHO, helpful in preventing epidemic

Covid-19 Oral Antiviral Treatments: A new drug made by India’s leading pharmaceutical company Hetero to prevent corona has been approved by the World Health Organization (WHO). The generic version of Hetero’s Kovid-19 oral antiviral treatment Nirmatrelvir has come, which the company has described as helpful in fighting Coronavirus. However, people will get this medicine only on the advice of a doctor. Hetero has launched a combo pack in the form of an oral drug ‘Nirmacom’.

It has been said by the World Health Organization (WHO) that India’s leading pharmaceutical company Hetero has made a medicine to prevent the corona epidemic. Hetero’s ‘Nirmacom’ is the generic version of Pfizer’s Kovid-19 oral antiviral drug ‘Paxlovid’. Today it is a good therapeutic option for high risk patients. However, the patient should take it only on the advice of the doctor.

Kovid will help in the war

Dr. Vamsi Krishna Bandi, Managing Director of Hetero Group of Companies in India said that the generic version of our Kovid-19 oral antiviral treatment Nirmatrelvir ‘Nirmacom’ has been approved by WHO. He said that this medicine will be helpful in the fight against Kovid. Dr. Vamsi said, “Getting WHO prequalification for our drug is an important milestone in the fight against COVID-19 as it allows us to bring this innovative antiretroviral drug to those in need.”

Focus on providing medicines at affordable prices

Dr. Vamsi said, “WHO has recommended Nirmatrelvir and Ritonavir for hospitalized high-risk patients as well as moderate and low-risk Covid patients. We are looking forward to making Nirmacom available rapidly in 95 LMICs at affordable prices. Committed to.” At the same time, in the statement of India’s leading pharmaceutical company Hetero, it was also told that the World Health Organization Prequalification of Medicines Program (WHO PQ) has approved the genetic version of our oral antiviral treatment Nirmatelvir, necessary to deal with COVID-19. It was said on behalf of the company that now the reach of our medicine will also be expanded.

Read also: From China to Japan… RT-PCR test is necessary for passengers coming from these countries, immediately quarantine if found positive